AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.